*The first dose may be given as early as 6 weeks of age.1
†The recommended dosing interval for the first, second, and third doses is 4 to 8 weeks.1
‡The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.1
AAP=American Academy of Pediatrics; ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention.
For children 7 months through 5 years of age who have not received Prevnar® (PCV7)§ or Prevnar 13®, one of the following three catch-up schedules should be used based on the child’s age when administered the first dose.1
For children and adolescents 6 years through 17 years of age who have not previously received Prevnar 13®, Prevnar 13® should be administered as a single dose.1
§Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein).
Patients who receive their third dose between 7 and 11 months are almost twice as likely to miss their fourth dose or receive it late compared to those who receive it on time4||¶
||Based on an Optum Q4 2018 post hoc analysis of 2018 calendar year electronic healthcare records (EHR) of children aged 19-35 months who received the Prevnar 13® third dose in 2018, derived from healthcare provider organizations covering 97 million adult and pediatric patients in the US.
¶According to the CDC, the fourth dose is not indicated if third dose is received ≥12 months after birth.5
Consider how a reminder-recall program may help improve childhood vaccination rates in your practice
Optum’s longitudinal clinical repository from Humedica is derived from healthcare provider organizations in the US that include more than 700 hospitals and 7000 clinics treating more than 97 million patients receiving care. The data are certified as de-identified by an independent statistical expert following HIPAA statistical de-identification rules, and managed according to Optum's customer data use agreements. Clinical claims and other medical administrative data are obtained from both inpatient and ambulatory electronic health records (EHR), practice management systems, and numerous other internal systems, and are processed, normalized, and standardized across the continuum of care from both acute inpatient stays and outpatient visits. Optum's data elements include demographics; medications prescribed and administered; immunizations; allergies; lab results (including microbiology); vital signs and other observable measurements; clinical and inpatient stay administrative data; and coded diagnoses and procedures. In addition, Optum uses natural language processing (NLP) computing technology to extract critical facts from physician notes into usable datasets. The NLP data provide detailed information regarding signs and symptoms, family history, disease-related scores (eg, RAPID3 for rheumatoid arthritis or CHADS2 for stroke risk), genetic testing, medication changes, and physician rationale behind prescribing decisions that might never be recorded in the EHR.1
Scheduling the fourth dose at 12 months allows for unforeseen delays, and therefore may help with timely completion of the full series4††
The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.1
**The decrease of 12 percentage points from 64% at month 12 to 52% at month 15 represents an 18% decrease in well visit attendance.
#Based on a national Blue Cross Blue Shield analysis of 843,610 commercially insured children born between 2010 and 2013 receiving medical services between birth and December 31, 2016. Children are counted as fully immunized upon receiving the needed vaccine(s) by age 27 months, allowing 9 months of buffer time for parents/guardians running behind schedule to take their children to their physician to receive their vaccines. A series of 7 CDC-recommended vaccines was chosen as a summary measure.6
††In children 6 years through 17 years of age, Prevnar 13® should be administered as a single dose.1
The fourth dose should be administered at approximately 12 to 15 months of age and at least 2 months after the third dose.
‡‡Comprises patients who are uninsured or receiving coverage from Medicare, Medicaid, or other undefined payers.1
To stock Prevnar 13®, call 1-800-666-7248 or click here
Offer resources that may help improve adherence to the CDC-recommended vaccination schedule
Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.
Please see full Prescribing Information for Prevnar 13®.
Limitations of Use and Effectiveness
Limitations of Use and Effectiveness